# Bob T. Li

Source: https://onco.cc/people/bob-li/  
OnCo record `bob-li` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ran the trials that made trastuzumab deruxtecan the first HER2-directed drug for lung cancer.

## Summary

Bob T. Li is a Medical Oncologist in Thoracic Oncology and Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center. He is known for leading DESTINY-Lung01, the trial that established trastuzumab deruxtecan as the first HER2-directed drug for HER2-mutant non-small-cell lung cancer, and for early studies of HER2-directed therapy in lung cancer. His selected paper reports trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. He continues to work on antibody-drug conjugates and early drug development while leading MSK's partnerships across the Asia-Pacific region.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Physician Ambassador to China and Asia-Pacific; Medical Oncologist, Thoracic Oncology
- Specialisms: HER2-mutant lung cancer; Antibody-drug conjugates; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Li%20BT%5BAuthor%5D

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [DESTINY-Lung01](https://onco.cc/trials/destiny-lung01/)

---
JSON: https://onco.cc/api/v1/entities/bob-li.json